LifeTech Scientific Corporation (LifeTech, 01302.HK), a leading company 
specialized in minimally invasive interventional medical devices for 
cardio-cerebrovascular and peripheral vascular diseases, today announced 2021 
interim results.

Compared with the first half of 2020, LifeTech achieved an outstanding 
performance. The revenue was approximately RMB461.1 million, increased by 
approximately 68.9%, the gross profit and the net profit was recorded 
approximately RMB374.4 million and RMB204.4 million respectively, representing 
an increase of around 72.5% and 106.5% respectively. 

In the first half of 2021, the sales generated from mainland China was 
increased by approximately 74.6% and it accounted for approximately 84.0% of 
the total revenue. Although the COVID-19 epidemic situation in most overseas 
markets remained unstable, the overseas sales still increased by approximately 
44.3% as compared with the corresponding period of 2020. 

As the performance of business segments, in the first half of 2021, the 
turnover contributed by the structural heart diseases business was 
approximately RMB159.1 million, representing an increase of approximately 
100.6%, of which the sales of LAA occluder increased by approximately 147.5% 
and the sales of the three CHD occluders: HeartR™, Cera™ and CeraFlex™ 
increased by approximately 47.3%,160.0% and 13.3% respectively.

LifeTech's peripheral vascular disease business generated the turnover of 
approximately RMB286.8 million, representing an increase of approximately 
50.0%, of which the sales of stent grafts and vena cava filters increased by 
approximately 60.8% and 24.7% respectively.

The turnover contributed by the cardiac pacing and electrophysiology business 
was approximately RMB15.2 million, representing a growth of approximately 
508.0%.

LifeTech continuously strengthened its innovation capabilities and accelerated 
the R&D process of its pipeline products to maintain its leading position in 
the industry, the R&D expenses increased by approximately 25.3% to 
approximately RMB91.7 million in the first half of 2021, and achieved the 
following main progress: 

G-iliac™ Iliac Artery Bifurcation Stent Graft System, LAnavi™ Jointed Steerable 
Introducer, Freepath™Guidance System and OKcurve™ Steerable Delivery System 
obtained official registration approval from the China NMPA; 
Xuper™ Open Surgery Stent Graft System obtained the CE certification in EU; 
IBS Angel™ Iron Bioresorbable Scaffold System ("IBS Angel™") obtained 
registration approval from Medical Device Authority in Malaysia; 
Artery Stent Graft System (chimney graft) was approved as an innovative medical 
device in China; 
Cinenses™ Lung Volume Reduction Reverser System has completed the enrollment of 
clinical trials in Europe; 
G-Branch™Thoraco-Abdominal Aortic Stent Graft System has completed the 
enrollment of FIM study and the mid-term follow-up results are positive; 
LAmbre™ LAA Occluder System, IBS Titan™ Sirolimus-Eluting Iron Bioresorbable 
Peripheral Scaffold System and IBS Angel™ were approved in the United States by 
the FDA for "Compassionate Use", and 
IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System obtained the 
implied permission for conducting confirmatory clinical trials in China.
Meanwhile, the total of 1,350 patent applications have been filed, of which 496 
patents have been registered as at 30 June 2021, which is an important 
intangible asset and an internal driving force of LifeTech improving its core 
competitiveness in the global device market.


Source: LifeTech Scientific Corporation